1908409-18-6
1908409-18-6
Chemical Structure
DOTA Zoledronate
- CAS. Nr.: 1908409-18-6
- Formula:C23H41N7O14P2
- Molecular Weight:701.56
IUPAC Name: 2,2',2''-(10-(2-((2-(1-(2-hydroxy-2,2-diphosphonoethyl)-1H-imidazol-4-yl)ethyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid
InChIKey: BRTYHOUKEJCOEE-UHFFFAOYSA-N
SMILES: O=C(CN1CCN(CCN(CCN(CC1)CC(O)=O)CC(NCCC2=CN(CC(P(O)(O)=O)(O)P(O)(O)=O)C=N2)=O)CC(O)=O)O
Biological Activity: DOTA Zoledronate is a next-generation agent for bone targeted radionuclide therapy for diagnosing bone metastases[1].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
DOTA Zoledronate | DOTA Zoledronate is a next-generation agent for bone targeted radionuclide therapy for diagnosing bone metastases. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
